ANDA Submission Process: Step-by-Step Guide for Generic Drug Approval

ANDA Submission Process: Step-by-Step Guide for Generic Drug Approval

Key Takeaways

Regulatory Basis for the ANDA Submission Process

The legal authority for the ANDA submission process originates from the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act). This legislation created a streamlined approval pathway for generic drugs by allowing applicants to rely on FDA's previous finding of safety and effectiveness for the reference listed drug (RLD).

Key regulatory references governing the ANDA process:

The ANDA pathway differs fundamentally from the 505(b)(1) NDA because the applicant does not need to independently establish safety and efficacy. Instead, the applicant must demonstrate that its product is pharmaceutically equivalent and bioequivalent to the RLD, which under 21 CFR 320.1 means it will deliver the same therapeutic effect in patients.

Pre-Submission Activities: Setting the Foundation

Before assembling an ANDA, applicants must complete several foundational activities. Failures at this stage are the most common source of complete response letters (CRLs) and extended review timelines.

1. Reference Listed Drug Selection

The first step is identifying the correct RLD in the FDA Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations). The RLD is the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.

Key considerations for RLD selection:

• The RLD must be listed in the Orange Book as an approved drug under Section 505(b) or 505(j)
• The proposed generic must have the same active ingredient, dosage form, route of administration, and strength as the RLD
• If the RLD has been withdrawn from the market for safety or effectiveness reasons, no ANDA may reference it (21 CFR 314.101(d)(1))
• For products where the RLD has been discontinued but not for safety reasons, FDA may still permit ANDA referencing per the "forfeiture" and "withdrawal" distinction

2. Suitability Petition Assessment

If the proposed generic product differs from the RLD in dosage form, route of administration, or strength, the applicant must evaluate whether an ANDA or 505(b)(2) pathway is appropriate and may need to file a suitability petition under Section 505(j)(2)(C) of the FD&C Act and 21 CFR 314.93 before submitting an ANDA. FDA has 90 days to respond to a suitability petition.

A suitability petition is not required if the only difference is:

• Active ingredient (in which case a 505(b)(2) NDA is needed, not an ANDA)
• Indication (labeling carve-out may be used instead)

3. Patent and Exclusivity Analysis

Before filing, applicants must analyze the Orange Book patent and exclusivity listings for the RLD:

4. Bioequivalence Strategy

The applicant must determine the appropriate bioequivalence approach. OGD publishes product-specific guidances (PSGs) that specify the recommended BE study design for each RLD.

Common BE approaches:

• In vivo pharmacokinetic study: Most common; crossover design comparing generic to RLD in healthy volunteers
• In vitro dissolution (BCS-based biowaiver): Available under 21 CFR 320.22(b)(2) for BCS Class 1 and certain Class 3 drugs
• In vivo pharmacodynamic study: For locally acting drugs where blood levels do not reflect activity
• Comparative clinical endpoint study: For complex products where PK and PD approaches are not feasible

5. Pre-ANDA Meeting with OGD

Under GDUFA III, applicants may request pre-ANDA meetings with OGD to discuss product development and regulatory strategy. There are three types:

GDUFA III introduced a "Pre-ANDA Program Facilitated Meeting" pathway that provides written responses to product-specific development questions.

ANDA Application Structure and Content Requirements

The content requirements for an ANDA are specified in 21 CFR 314.94. The application must be submitted electronically in eCTD format through FDA's Electronic Submissions Gateway (ESG).

Required ANDA Sections per 21 CFR 314.94

Module 1: Administrative Information

• Form FDA 356h (Application to Market a New Drug)
• GDUFA cover sheet and user fee payment
• Patent certifications or statements for each Orange Book-listed patent
• Paragraph IV certification notice letters (if applicable)
• Labeling (draft and annotated side-by-side comparison with RLD)
• Environmental assessment or claim of categorical exclusion per 21 CFR 25.31
• Right of reference letters (if referencing a DMF)

Module 2: Summaries

• Quality Overall Summary (QOS)
• Bioequivalence summary

Module 3: Quality (CMC)

• Drug substance information (S section)
• Drug product information (P section)
• Manufacturing process description and validation
• Specification and analytical methods
• Stability data per ICH Q1A(R2) guidelines
• Container closure system information
• Reference to Drug Master Files (DMFs) if applicable

Module 5: Clinical Study Reports

• Bioequivalence study reports
• Bioanalytical method validation
• Statistical analysis of BE data

Labeling Requirements

ANDA labeling must be the same as the RLD labeling, with certain exceptions:

• Section viii Statement: The ANDA applicant may carve out (omit) patented indications or methods of use from its labeling under 21 CFR 314.94(a)(8)(iv)
• Trade name and manufacturer information: Must reflect the generic applicant
• Established name: Required in lieu of trade name per 21 CFR 299.4
• Bioequivalence information: Not included in labeling
• Inactive ingredients: May differ from RLD but must be suitable for the dosage form

Filing an ANDA: Electronic Submission Requirements

All original ANDA submissions must be submitted electronically in eCTD format through FDA's Electronic Submissions Gateway (ESG). FDA no longer accepts paper ANDA submissions.

eCTD Submission Specifications

Filing Checklist

Before submitting, confirm the following elements are included and complete:

• [ ] Form FDA 356h completed and signed
• [ ] GDUFA cover sheet with payment confirmation
• [ ] Patent certification statements for all Orange Book-listed patents
• [ ] Paragraph IV notice letters sent to patent holders and NDA holder (if applicable)
• [ ] Annotated comparison labeling
• [ ] Environmental assessment or categorical exclusion claim
• [ ] Complete CMC data package with stability data
• [ ] Bioequivalence study report with statistical analysis
• [ ] Bioanalytical method validation report
• [ ] DMF authorization letters (if referencing DMFs)
• [ ] Debarment certification per 21 CFR 314.94(a)(11)
• [ ] Financial disclosure per 21 CFR Part 54

OGD Refuse-to-Receive Criteria

After an ANDA is submitted, OGD conducts an initial screening to determine whether the application meets minimum standards for acceptance. This refuse-to-receive (RTR) review is completed within 60 days of submission under GDUFA commitments.

RTR Criteria per FDA Guidance

FDA's "Refuse to Receive Standards and Criteria" guidance specifies the deficiencies that trigger RTR:

Grounds for Refuse to Receive:

RTR is not issued for:

• Scientific deficiencies that require review (these result in CRLs)
• Minor formatting issues
• Missing information that can be requested via Information Request (IR)

OGD Review Process: From Filing to Approval

Once an ANDA passes RTR screening, it enters OGD's multi-discipline review process. Under GDUFA III, OGD has committed to specific review timeline goals.

Review Timeline Goals (GDUFA III, FY2023-2027)

Multi-Discipline Review Steps

The OGD review involves parallel assessments by multiple review disciplines:

1. Chemistry Review (Office of Pharmaceutical Quality)

• Drug substance characterization and specification
• Drug product formulation, manufacturing, and controls
• Stability data assessment
• Container closure system evaluation
• Manufacturing facility inspection readiness

2. Bioequivalence Review (Office of Clinical Pharmacology)

• BE study design adequacy
• Bioanalytical method validation
• Pharmacokinetic data analysis
• Statistical evaluation (90% CI within 80-125% for log-transformed AUC and Cmax)
• Dissolution profile comparison

3. Labeling Review (Office of Generic Drugs)

• Comparison with current RLD labeling
• Accuracy of Section viii carve-outs
• Compliance with 21 CFR 201 requirements
• Established name and proprietary name assessment

4. Microbiology Review (if applicable)

• Antimicrobial products
• Preservative effectiveness
• Sterility assurance for sterile products

5. Plant Evaluation (Office of Regulatory Affairs)

• Pre-approval inspection (PAI) of manufacturing facilities
• Current Good Manufacturing Practice (cGMP) compliance
• Data integrity verification

Review Outcomes

Paragraph Certifications and Patent Challenges

The ANDA submission process requires applicants to address every patent listed in the Orange Book for the RLD. Under 21 CFR 314.94(a)(12), four types of certifications are available:

The Four Paragraph Certifications

Paragraph IV Certification Process

When an ANDA includes a Paragraph IV certification, the applicant must:

1. Notify the patent holder and NDA holder within 20 days after ANDA submission is accepted (21 CFR 314.95)
2. Include a detailed statement of the factual and legal basis for the opinion that the patent is invalid, unenforceable, or not infringed
3. Withstand potential patent litigation: The patent holder has 45 days from receipt of notice to file a patent infringement suit
4. Navigate the 30-month stay: If suit is filed within 45 days, FDA approval is stayed for 30 months (or until court decision, whichever comes first)

GDUFA User Fees: What They Cost

The Generic Drug User Fee Amendments (GDUFA) require ANDA applicants to pay user fees that fund FDA's generic drug review activities.

GDUFA III Fee Structure (FY2026)

Fee amounts are adjusted annually by FDA and published in the Federal Register.

Common ANDA Submission Pitfalls and How to Avoid Them

Based on OGD review data and published complete response letter trends, the most frequent ANDA deficiencies include:

Top Deficiency Categories

Strategies for First-Cycle Approval

While OGD's first-cycle approval rate is low, applicants can improve their odds by:

1. Using OGD's product-specific guidances as the definitive reference for BE study design
2. Requesting a Pre-ANDA meeting for complex products to align on development expectations
3. Conducting a mock RTR review internally before submission
4. Ensuring all DMF holders have authorized reference and that DMF content is current
5. Submitting the most current RLD labeling from DailyMed, not outdated versions
6. Providing complete stability data covering at least 6 months of accelerated and 12 months of long-term data at the time of ANDA submission

Post-Submission: Amendments, Supplements, and Lifecycle Management

During Review: Amendments

If OGD identifies deficiencies during review, it may issue:

• Information Request (IR): Request for additional information; does not reset the review clock unless classified as a major amendment
• Discipline Review Letter (DRL): Notification of deficiency in a specific review area
• Complete Response Letter (CRL): Formal notification that ANDA cannot be approved in current form

Amendment classifications and timeline impact:

Post-Approval Changes: Supplements

After ANDA approval, changes to the approved application require supplements:

Post-approval supplement requirements are governed by 21 CFR 314.70 and FDA's SUPAC guidances (Scale-Up and Post-Approval Changes).

ANDA Submission Process Timeline Summary

References